Charles Schwab Misses by a Penny – Analyst Blog
Zacks Market Commentaries (October 16th, 2009) Writes:
Analyst, cent;, Charles Schwab Corporation, Investing Lessons, Stocks to Watch, USD, Zacks Market Commentaries
Zacks Market Commentaries (October 16th, 2009) Writes:
stock-pr (August 14th, 2009) Writes:
The Charles Schwab Corporation released its Monthly Market Activity Report today. Company highlights for the month of July 2009 include:
* Net new assets brought to the company by new and existing clients in July 2009 totaled $5.6 billion. * Total client assets were $1.286 trillion as of month-end July, down 8% from July 2008 and up 5% from June 2009. * Client daily average trades were 291.1 thousand in July 2009, down 14% from July 2008 and down
The SMART report can be viewed with its accompanying 12-month data at http://www.aboutschwab.com/investor/financials/financial_reports.html
About Charles Schwab
The Charles Schwab Corporation (Nasdaq:SCHW - News) is a leading provider of financial services, with more than 300 offices and 7.6 million client brokerage accounts, 1.5 million corporate retirement plan participants, 619,000 banking accounts, and $1.3 trillion in client assets. Through its operating subsidiaries, the company provides a full range of securities brokerage, banking, money management and financial
...
Zacks Market Commentaries (July 13th, 2009) Writes:
Zacks Market Commentaries (June 29th, 2009) Writes:
Chicago, IL - June 29, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca (AZN), Darden Restaurants, Inc. (DRI), Charles Schwab Corporation (SCHW), Stein Mart (SMRT) and Shire (SHPGY).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday's Analyst Blog:
AstraZeneca's Pipeline Must Deliver
We currently rate shares of AstraZeneca (AZN) a Hold with a $47 price target. The company is facing a number of challenges as it enters 2009, most notably generic competition to Toprol-XL, Nexium, Casodex and Pulmicort.
The just-announced increase
...
Zacks Market Commentaries (June 26th, 2009) Writes: